Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth
02:08am, Tuesday, 10'th Feb 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance across all major regions and...
Drugmaker AstraZeneca forecasts sales and profit growth in 2026
02:06am, Tuesday, 10'th Feb 2026
AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
12:41pm, Monday, 09'th Feb 2026
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Nasdaq powers ahead, Dow Jones notches new closing record
11:10am, Monday, 09'th Feb 2026
4:10pm: Fresh highs Another strong day on Wall Street saw the Dow Jones notch a new closing record of 50,136, up 20 points. The Nasdaq added 0.9% at 23,238...
Nasdaq powers ahead as Dow adds to gains in afternoon trading
09:23am, Monday, 09'th Feb 2026
2:20pm: Market movers Workday Inc. (WDAY) shares slid more than 6% after the company said co-founder Aneel Bhusri will return as CEO, replacing Carl...
Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal
07:29am, Monday, 09'th Feb 2026
Eli Lilly (LLY) has agreed to pay $350 million upfront to partner with Innovent Biologics on the joint development of new therapies targeting cancer and immune
Dow Jones retreat from highs as Amazon and Apple fall
05:44am, Monday, 09'th Feb 2026
10:40am: Week ahead Wall Street is heading into another crowded and potentially volatile week, with investors juggling a heavy earnings calendar, a backlog...
Oakmark International Strategy Q4 2025 New Investments And Divestments
12:20pm, Sunday, 08'th Feb 2026
Oakmark International Strategy Q4 2025 New Investments And Divestments
Wall Street Week Ahead
05:59am, Sunday, 08'th Feb 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Broker initiates coverage of Capita with a 'buy' call
06:40am, Friday, 06'th Feb 2026
Capita PLC (LSE:CPI) received a boost after Shore Capital Markets initiated coverage of the UK outsourcing group with a Buy rating, arguing that the company's turnaround plan could support a return t
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:16am, Thursday, 05'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
09:35am, Thursday, 05'th Feb 2026
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
Contrasting AstraZeneca (NASDAQ:AZN) and Onconetix (NASDAQ:ONCO)
01:34am, Thursday, 05'th Feb 2026
Onconetix (NASDAQ: ONCO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based o
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
11:16am, Wednesday, 04'th Feb 2026
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
07:15pm, Tuesday, 03'rd Feb 2026
The latest trading day saw Astrazeneca (AZN) settling at $184.32, representing a -2.17% change from its previous close.
